← Leaderboards
Mitchell J Weiss
Children'S Hospital Of Philadelphia
$27,379,685
Attributed
$43,112,259
Total exposure
20
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,071,435 · 22
By mechanism
R01$23,577,525 · 9
P01$17,888,720 · 3
R24$6,722,389 · 2
P30$4,435,923 · 2
U01$3,710,340 · 1
RC2$1,962,019 · 1
Top collaborators
- Gerd A Blobel11 shared
- Ross C Hardison11 shared
- James Peter Taylor10 shared
- Yu Zhang10 shared
- David M. Bodine6 shared
- David R Liu6 shared
- Francesca Chiaromonte5 shared
- Webb Colby Miller5 shared
Most similar at Children'S Hospital Of Philadelphia
Same institution · by research overlap
- Nancy Bettina Spinner$12,380,489
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightHemoglobinCellsGenesErythrocytesErythroidErythropoiesisGeneticProductionProteinsHematopoietic Stem CellsAffectBloodIn VitroMutationIn VivoAdultGene ExpressionErythroid CellsBiologyComplexAnemiaRegulationFunctional Disorder
Grant awards (95)
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,183,000
U01 · FY2025 · HL · contact PI
Base editing and prime editing for sickle cell disease$830,254
R01 · FY2025 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$779,601
R01 · FY2025 · HL
ULK-mediated autophagy of α-globin in Ã-thalassemia$652,585
R01 · FY2025 · HL · contact PI
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$185,000
U01 · FY2025 · HL · contact PI
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,159,340
U01 · FY2024 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$764,009
R01 · FY2024 · HL
Base editing and prime editing for sickle cell disease$761,516
R01 · FY2024 · HL · contact PI
ULK-mediated autophagy of α-globin in Ã-thalassemia$639,532
R01 · FY2024 · HL · contact PI
Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease$1,183,000
U01 · FY2023 · HL · contact PI
Clonal hematopoiesis and inherited genetic variation in sickle cell disease$817,595
R01 · FY2023 · HL
Base editing and prime editing for sickle cell disease$777,057
R01 · FY2023 · HL · contact PI
ULK-mediated autophagy of α-globin in Ã-thalassemia$652,585
R01 · FY2023 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders$2,722,946
P01 · FY2022 · HL · contact PI
Lentiviral Gene Therapy And Genome Editing for Sickle Cell Disease$788,242
P01 · FY2022 · HL · contact PI
Base editing and prime editing for sickle cell disease$715,670
R01 · FY2022 · HL · contact PI
ULK-mediated autophagy of α-globin in Ã-thalassemia$652,585
R01 · FY2022 · HL · contact PI
PedGeneRx - Admin Supplement to Base Editing and Prime Editing for Sickle Cell Disease R01$182,000
R01 · FY2022 · HL · contact PI
Administrative Core$31,722
P01 · FY2022 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders$2,728,503
P01 · FY2021 · HL · contact PI
Lentiviral Gene Therapy And Genome Editing for Sickle Cell Disease$790,945
P01 · FY2021 · HL · contact PI
Base editing and prime editing for sickle cell disease$733,558
R01 · FY2021 · HL · contact PI
Administrative Core$31,672
P01 · FY2021 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders$2,734,318
P01 · FY2020 · HL · contact PI
VISION: ValIdated Systematic IntegratiON of epigenomic data$1,183,458
R24 · FY2020 · DK
Lentiviral Gene Therapy And Genome Editing for Sickle Cell Disease$793,960
P01 · FY2020 · HL · contact PI
Administrative Core$31,618
P01 · FY2020 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders$2,750,038
P01 · FY2019 · HL · contact PI
VISION: ValIdated Systematic IntegratiON of epigenomic data$1,202,598
R24 · FY2019 · DK
Lentiviral Gene Therapy And Genome Editing for Sickle Cell Disease$796,486
P01 · FY2019 · HL · contact PI
Administrative Core$31,632
P01 · FY2019 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease And Immunodeficiency Disorders$2,804,656
P01 · FY2018 · HL · contact PI
VISION: ValIdated Systematic IntegratiON of epigenomic data$1,219,282
R24 · FY2018 · DK
Lentiviral Gene Therapy And Genome Editing for Sickle Cell Disease$820,402
P01 · FY2018 · HL · contact PI
Trim58 and the Ubiquitin Proteasome System in Erythro-megakaryopoiesis$380,625
R01 · FY2018 · DK · contact PI
Administrative Core$31,580
P01 · FY2018 · HL · contact PI
VISION: ValIdated Systematic IntegratiON of epigenomic data$1,232,180
R24 · FY2017 · DK
Mechanisms of Heterocellular Signaling at the Myoendothelial Junction$520,415
R01 · FY2017 · HL
Trim58 and the Ubiquitin Proteasome System in Erythro-megakaryopoiesis$380,625
R01 · FY2017 · DK · contact PI
2017 Red Cells Gordon Research Conference & Gordon Research Seminar$20,000
R13 · FY2017 · DK · contact PI
VISION: ValIdated Systematic IntegratiON of epigenomic data$1,324,873
R24 · FY2016 · DK
Mechanisms of Heterocellular Signaling at the Myoendothelial Junction$404,587
R01 · FY2016 · HL
Trim58 and the Ubiquitin Proteasome System in Erythro-megakaryopoiesis$380,625
R01 · FY2016 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$338,188
R01 · FY2016 · DK · contact PI
Mechanisms of Heterocellular Signaling at the Myoendothelial Junction$401,074
R01 · FY2015 · HL
Trim58 and the Ubiquitin Proteasome System in Erythro-megakaryopoiesis$380,625
R01 · FY2015 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$338,768
R01 · FY2015 · DK · contact PI
Core B: Human Stem Cell Core$124,738
P30 · FY2015 · DK · contact PI
Towards Precision Medicine in Childhood Acquired Aplastic Anemia$559,998
R24 · FY2014 · DK
Mechanisms of Heterocellular Signaling at the Myoendothelial Junction$424,201
R01 · FY2014 · HL
Core B: Human Stem Cell Core$411,039
P30 · FY2014 · DK · contact PI
Trim58 and the Ubiquitin Proteasome System in Erythro-megakaryopoiesis$380,625
R01 · FY2014 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$360,671
R01 · FY2014 · DK · contact PI
Global Predictions and Tests of Hematopoietic Regulation$224,250
R56 · FY2014 · DK
Human Hematopoietic Stem Cell Center of Excellence$1,053,727
P30 · FY2013 · DK · contact PI
Global Predictions and Tests of Erythroid Regulation$555,662
R01 · FY2013 · DK
Regulation of erythropoiesis by the miR-144/451 microRNA locus$351,562
R01 · FY2013 · DK · contact PI
Core B: Human Stem Cell Core$312,556
P30 · FY2013 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$62,693
R01 · FY2013 · DK · contact PI
Human Hematopoietic Stem Cell Center of Excellence$47,806
P30 · FY2013 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$1
R01 · FY2013 · DK · contact PI
Human Hematopoietic Stem Cell Center of Excellence$1,117,182
P30 · FY2012 · DK · contact PI
Global Predictions and Tests of Erythroid Regulation$575,817
R01 · FY2012 · DK
Core B: Human Stem Cell Core$411,039
P30 · FY2012 · DK · contact PI
Regulation of erythropoiesis by the miR-144/451 microRNA locus$364,313
R01 · FY2012 · DK · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$338,442
R01 · FY2012 · DK · contact PI
Global Predictions and Tests of Erythroid Regulation$575,817
R01 · FY2011 · DK
Core B: Human Stem Cell Core$418,707
P30 · FY2011 · DK · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$338,442
R01 · FY2011 · DK · contact PI
Hematopoiesis from Normal and Patient-Derived Induced Pluripotent Stem Cells$964,802
RC2 · FY2010 · HL · contact PI
Global Predictions and Tests of Erythroid Regulation$685,235
R01 · FY2010 · DK
Core B: Human Stem Cell Core$539,129
P30 · FY2010 · DK · contact PI
The Role of Alpha Hemoglobin Stabilizing Protein in Human Beta Thalassemia$411,250
R01 · FY2010 · HL · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$341,861
R01 · FY2010 · DK · contact PI
Hematopoiesis from Normal and Patient-Derived Induced Pluripotent Stem Cells$997,217
RC2 · FY2009 · HL · contact PI
Global Predictions and Tests of Erythroid Regulation$706,720
R01 · FY2009 · DK
The Role of Alpha Hemoglobin Stabilizing Protein in Human Beta Thalassemia$411,250
R01 · FY2009 · HL · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$345,313
R01 · FY2009 · DK · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$8,111
R01 · FY2009 · DK · contact PI
The Role of Alpha Hemoglobin Stabilizing Protein in Human Beta Thalassemia$411,979
R01 · FY2008 · HL · contact PI
Molecular and Biological Activities of Alpha Hemoglobin Stabilizing Protein$361,682
R01 · FY2008 · DK · contact PI
The Role of Alpha Hemoglobin Stabilizing Protein in Human Beta Thalassemia$412,500
R01 · FY2007 · HL · contact PI
Transcription Factor GATA-1 in Erythro-Megakaryocytic Development and Leukemia$200,269
R21 · FY2007 · DK · contact PI
The function and regulation of alpha hemoglobin stabilizing protein (AHSP) in hem$82,500
R56 · FY2007 · DK · contact PI
Characterization of a alpha-globin chaperone protein$346,899
R01 · FY2006 · DK · contact PI
Transcription Factor GATA-1 in Erythro-Megakaryocytic De$247,500
R21 · FY2006 · DK · contact PI
Antiproliferative actions of GATA-1 during hematopoiesis$243,149
R01 · FY2006 · DK · contact PI
Characterization of a alpha-globin chaperone protein$355,247
R01 · FY2005 · DK
Antiproliferative actions of GATA-1 during hematopoiesis$249,000
R01 · FY2005 · DK
Characterization of a alpha-globin chaperone protein$355,247
R01 · FY2004 · DK
Antiproliferative actions of GATA-1 during hematopoiesis$249,000
R01 · FY2004 · DK
Characterization of a alpha-globin chaperone protein$355,247
R01 · FY2003 · DK
Characterization of a alpha-globin chaperone protein$104,747
R01 · FY2003 · DK
Characterization of a alpha-globin chaperone protein$34,000
R01 · FY2003 · DK
Characterization of a alpha-globin chaperone protein$376,763
R01 · FY2002 · DK